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Selective serotonin reuptake inhibitors (SSRI) are established first-line pharmacological
treatments for obsessive-compulsive disorder (OCD), while antipsychotics are used as an
augmentation strategy for SSRI in OCD patients who have either no response or a partial
response to SSRI treatment. The goal of the present study was to identify genetic variants
and pathways that are associated with the long-term clinical response of OCD patients to
SSRI or SSRI with antipsychotics.
Methods
We first performed a genome-wide association study of 96 OCD patients to examine genetic
variants contributing to the response to SSRI or SSRI with antipsychotics. Subsequently,
we conducted pathway-based analyses by using Improved Gene Set Enrichment Analysis
for Genome-wide Association Study (i-GSEA4GWAS) to examine the combined effects of
genetic variants on the clinical response in OCD.
Results
While we failed to detect specific genetic variants associated with clinical responses to
SSRI or to SSRI with an atypical antipsychotic at genome-wide levels of significance, we
identified 8 enriched pathways for the SSRI treatment response and 5 enriched pathways
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for the treatment response to SSRI with an antipsychotic medication. Notably, the calcium
signaling pathway was identified in both treatment responses.
Conclusions
Our results provide novel insight into the molecular mechanisms underlying the variability in
clinical response to SSRI and SSRI with antipsychotics in OCD patients.
Introduction
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder that occurs in approxi-
mately 2% of the population, and is characterized by repetitive, persistent, intrusive thoughts
and repetitive, compulsive behaviors [1]. Selective serotonin reuptake inhibitors (SSRIs) are the
most common first-line treatment for OCD [2], and antipsychotics have been proposed as aug-
menting agents in OCD patients who have either no response or a partial response to SSRI
treatment. However, how to use antipsychotic drugs, such as the choice, optimal dose, and
duration, has not been still established [3,4,5,6]. However, because of the variability in treat-
ment response among OCD patients, and because several weeks are needed to reveal the effi-
cacy of medications, the identification of biomarkers that predict treatment responses would
enhance treatment outcomes in these individuals. While previous pharmacogenomics studies
have focused on candidate biomarker genes, such as BDNF (brain-derived neurotrophic fac-
tor), COMT (catechol-O-methyltransferase), CYP2D6 (cytochrome P450, family 2, subfamily
D, polypeptide 6), and SLC6A4 [solute carrier family 6 (neurotransmitter transporter), member
4], the results of these analyses have been inconsistent [7].
Genome-wide association study (GWAS) is an approach to examine the association
between the particular trait and hundreds of thousands of single nucleotide polymorphisms
(SNPs) across the genomes in different individuals at the same time, and have identified many
genetic locus association with many complex diseases [8].
To date, only one GWAS has examined treatment responses to serotonin reuptake inhibi-
tors (SRIs) in OCD patients [9]. Notably, this group identified single-nucleotide polymorphism
(SNP), rs17162912, which is near the DISP1 gene, associated with SRI treatment responses at
genome-wide level of significance. In the current study, we aimed to further these findings by
identifying genetic variants contributing to the response to SSRI or SSRI combined with anti-
psychotics, via GWAS analysis of 96 OCD patients.
Materials and Methods
Subjects
Ninety-six OCD patients were recruited from Tokushima University Hospital in Japan, as
described in detail in a separate study [10]. All subjects who participated in this study were of
Japanese origin, and 10 subjects had not taken any psychotropic drugs. Diagnoses of OCD
were made according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
criteria by at least 2 expert psychiatrists. Clinical symptoms were evaluated at baseline and at
the end of treatment using the Yale Brown Obsessive-Compulsive Scale (Y-BOCS). The mean
follow up duration of this study was 13.1 ± 8.1 month. During the follow up period of this
study, all patients had taken medications without psychotherapy treatments. After treatment,
patients were divided into three groups according to their pharmacological response: group A
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was comprised of patients that exhibited>35% reduction in Y-BOCS scores after treatment
with a high dose of SSRI (fluvoxamine 200mg-300mg, paroxetine 40mg-60mg, sertraline
150mg-200mg, or escitalopram 20mg), while group B was comprised of patients that had either
no response or a partial response to SSRI treatment and exhibited a>35% reduction in
Y-BOCS scores after one low-dose antipsychotic augmentation treatment (risperidone
0.25mg-3mg, olanzapine 2.5mg-10mg, quetiapine 100mg, perospirone 4mg-8mg, or aripipra-
zole 3mg-24mg) combined with SSRI. The remaining patients, who responded neither to SSRI
treatment nor to SSRI treatment combined with antipsychotic augmentation comprised group
C. The institutional ethics committee of the University of Tokushima Graduate School
approved the current study and all subjects signed written, informed consent forms.
Genotyping and Quality Control
A total of 695,789 SNPs were genotyped for each subjects using the Illumina HumanOmniEx-
press-24v1-0 BeadChip according to the manufacturer’s instructions(Illumina, Inc., San Diego,
CA, USA). Quality control was conducted using PLINK v1.07 software. SNPs with call rates
< 95%, minor allele frequencies< 5%, and Hardy-Weinberg equilibrium test P-values< 10−6
were excluded from the subsequent association analysis. Individuals with excessive missing
genotypes, sex discrepancies, and cryptic duplicates were removed. After quality control, a total
of 505,934 SNPs from 93 individuals (46 males and 47 females) were subjected to further analy-
sis. We deposited genome-wide association study data to the Gene Expression Omnibus (GEO)
of the National Center for Biotechnology Information under the accession number GSE76611.
Statistical Analyses
To evaluate the effect of each SNP on the clinical response to SSRI (group A vs. group B plus C)
or to SSRI combined with antipsychotics (group B vs. group C), logistic regression analysis was
performed using PLINK v1.07 software, with adjustments for the following covariates: sex, age,
onset age, and Y-BOCS baseline score. Pathway-based analyses were conducted using i-
GSEA4GWAS v2 (http://gesa4gwas-v2.psycho.ac.cn/), a web server designed to enable func-
tional analysis of SNPs in trait-associated pathways identified by GWAS [11], using the SNPs
and P-values obtained from our GWAS. i-GSEA4GWAS employs SNP label permutation to
correct gene variation to reduce the bias due to different genes with different number of mapped
SNPs. This correction ensures to identify gene sets consisting of non-random high-association
genes with biological plausibility instead of random high-association genes with large numbers
of mapped SNPs [12]. This analysis has been applied in many studies [13,14,15,16,17]. The
parameters used for i-GSEA4GWAS v2 analysis were as follow: SNPs were mapped to the near-
est genes within their 20 kilobases (kb) upstream/downstream; the gene set/pathway databases
were from KEGG (http://www/genome.jp/kegg/) and BioCarta (http://www.biocarta.com); and
only gene sets/pathways comprising at least 20 and at most 200 genes were examined. A false
discovery rate (FDR) correction of 0.05 was applied for multiple testing. The pathways/gene sets
with FDR< 0.25 is regarded as ‘possible`or `hypothesis`, while the threshold of FDR< 0.05 is
regarded as ‘high confidence`or ‘with statistical significance`in this analysis [12].
Results
Demographics
After quality control, a total of 93 patients were divided into three groups according to their
pharmacological responses. Specifically, groups A, B, and C were comprised of, 56, 23, and 17
patients, respectively. The clinical characteristics of the patients in each group are summarized
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in Table 1. No significant differences in gender, age, onset age, or duration of illness was
observed among the three groups. However, significant differences were observed among the
groups in Y-BOCS scores at baseline and at the end of the treatment.
Genome-wide Association Study
After quality control, a total of 505,934 SNPs were examined in the present pharmacogenomics
study. Of these, 178 were nominally associated with the SSRI treatment response, and one was
nominally associated with the treatment response to SSRI in combination with an antipsy-
chotic medication (P< 1.0 × 10−3). However, none of these SNPs exhibited genome-wide levels
of significance (P< 5 × 10−8). The 10 SNPs exhibiting the strongest associations with each
treatment response are shown Table 2, and a list of SNPs with P values< 1.0 x 10−3 is included
in supplement file (S1 Table). Notably, rs6557479, which is located near the ARID1B (AT-rich
interactive domain 1B) gene, was among the 10 SNPs with the strongest associations with SSRI
treatment response. ARID1B encodes a DNA binding subunit of the Brahma-associated factor
chromatin remodeling complex, which plays a key role in the regulation of gene activity and
neurodevelopment [18], and mutations in this gene have been associated with autism, intellec-
tual disability, and developmental delay [19,20,21].
Meanwhile, the SNP that exhibited the strongest association with the response to SSRI com-
bination with antipsychotic medication was rs3812398, which is located in the CHN2 (chi-
merin 2; P = 8.9 × 10−4) gene. CHN2, which is expressed in a variety of human tissues but is
expressed at the highest levels in the brain, is GTPase-activating protein that plays an impor-
tant role in the establishment of functional brain circuitry by controlling axon pruning [22].
Mutations in this gene have been associated with schizophrenia and atypical psychosis [23,24].
Pathway Analysis
Table 3 lists the significantly enriched pathways for each treatment response. Eight pathways
were identified from the results of the GWAS for the SSRI treatment response, while 5 path-
ways were identified from the results of the GWAS for the treatment response to SSRI in
Table 1. Treatment response group and clinical symptoms of patients with obsessive-compulsive disorder.
A B C
(N = 54) (N = 22) (N = 17) total Pvalue
Sex (M), N (%) 24 (44.4) 12 (54.5) 10 (58.8) 46 0.51
Sex (F), N (%) 30 (55.6) 10 (45.5) 7 (41.2) 47
Age, mean (SD) 33.28 (12.84) 30.41 (11.33) 28.41 (9.86) 31.71(11.98) 0.3
Onset age, mean (SD) 25.07 (10.77) 23.14 (12.17) 18.00 (10.88) 23.32(11.26) 0.079
Duration of illness, mean (SD) 8.20 (9.29) 7.27 (6.17) 10.41 (10.03) 8.39(8.72) 0.53
Y-BOCS score
Baseline, mean (SD) 23.57 (4.85) 25.55 (4.62) 28.00 (4.30) 24.85(4.93) 0.003
After treatment, mean (SD) 8.28 (3.89) 11.36 (3.02) 25.12 (4.82) 12.08(7.37) <0.001
P-values are calculated by χ2 and ANOVA.
Duration of illness: length from onset of obsessive complusive disorder to start of treatment in Tokushima university hospital.
A: Responders to a selective serotonin reuptake inhibitor
B: Responders to a selective serotonin reuptake inhibitor with an atypical antipsychotic
C: Non-responders to a selective serotonin reuptake inhibitor with an atypical antipsychotic
doi:10.1371/journal.pone.0157232.t001
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Table 2. Association results of GWAS for the treatment response in OCD.
SSRI treatment response
SNP Chr Position Alleles MAF OR P Genomic Location Closest gene
rs6118017 20 7924726 [A/G] 0.4177 5.732 6.26×10–5 Intergenic HAO1
rs6557479 6 156502670 [T/C] 0.375 7.023 1.03×10–4 Intergenic ARID1B
rs11778051 8 141410497 [T/C] 0.4415 4.511 1.35×10–4 Intronic TRAPPC9
rs2876110 20 7947638 [A/G] 0.4266 4.897 1.39×10–4 Intergenic HAO1
rs10882614 10 97315080 [T/C] 0.1468 0.06546 1.41×10–4 Intronic SORBS1
rs2474028 14 92403660 [T/C] 0.2272 0.1973 1.46×10–4 Intronic FBLN5
rs7241999 18 31640468 [T/C] 0.4692 0.2053 1.57×10–4 Intronic NOL4
rs1543377 20 7951007 [T/G] 0.4216 4.773 1.87×10–4 Intergenic HAO1
rs7599124 2 174455978 [A/G] 0.2242 0.149 2.06×10–4 Intergenic CDCA7
rs1963569 4 169338520 [A/C] 0.253 0.2539 2.18×10–4 Intronic DDX60L
The treatment response to SSRI with an antipsychotic medication
SNP Chr Position Alleles MAF OR P Genomic Location Closest gene
rs3812398 7 29237994 [A/G] 0.2837 0.01382 8.92×10–4 Intronic CHN2
rs2004915 11 12127181 [T/C] 0.3363 0.04343 1.11×10–3 Intronic MICAL2
rs2838416 21 45252838 [T/C] 0.1954 0.0303 1.21×10–3 Intergenic AGPAT3
rs11914777 3 32334008 [T/C] 0.2004 0.04424 1.21×10–3 Intronic CMTM8
rs7955451 12 100005790 [T/G] 0.4683 0.07164 1.31×10–3 Intronic ANKS1B
rs1039378 12 99991075 [T/C] 0.4812 0.0374 1.32×10–3 Intronic ANKS1B
rs12151194 19 53552296 [A/C] 0.3313 0.04769 1.36×10–3 Intronic ERVV-2
rs6509718 19 53548950 [A/G] 0.3165 0.04769 1.36×10–3 Intronic ERVV-2
rs8128681 21 47049185 [T/C] 0.1567 0.04903 1.50×10–3 Intergenic PCBP3
rs6133566 20 8254666 [T/C] 0.3452 38.13 1.55×10–3 Intronic PLCB1
Chr, chromosome; MAF, minor allele frequency; NA, not applicable; OR, odds ratio; SNP, single-nucleotide polymorphism.
doi:10.1371/journal.pone.0157232.t002
Table 3. Pathway-based analysis for the results of GWAS for the treatment response in OCD.
SSRI treatment response
Gene Set Name P-value FDR value
Axon guidance (KEGG) 0.001 0.0125
FCER1 signaling pathway (BioCarta) 0.001 0.0128
Fc epsilon RI signaling pathway (KEGG) 0.001 0.0130
T cell receptor signaling pathway (KEGG) 0.001 0.0137
TCR pathway (BioCarta) 0.002 0.0438
Calcium signaling pathway (KEGG) 0.002 0.0459
NFAT pathway (BioCarta) 0.003 0.0489
GPCR pathway (BioCarta) 0.002 0.0497
The treatment response to SSRI with an antipsychotic medication
Gene Set Name P-value FDR value
Calcium signaling pathway (KEGG) 0.001 0.0070
Dilated cardiomyopathy (KEGG) 0.001 0.0345
Nitrogen metabolism (KEGG) 0.003 0.0347
mTOR pathway (BioCarta) 0.001 0.0365
Long-term potentiation (KEGG) 0.002 0.0418
Pathways with nominal P0.01 and FDR<0.05
doi:10.1371/journal.pone.0157232.t003
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combination with an antipsychotic medication (FDR values< 0.05). Among these pathways,
the calcium signaling pathway was significantly enriched in both treatment responses.
Discussion
While we identified suggestive 178 SNPs that had significant associations with long-term clini-
cal responses to SSRI in OCD patients, none of the associations exhibited the genome-wide lev-
els of significance. To reveal combined effects of SNPs on SSRI response, we conducted a
pathway-based analysis using our GWAS data and identified eight pathways associated with
treatment responses. Of these, the FCER1 pathway, the Fc epsilon RI signaling pathway, the T
cell receptor (TCR) signaling pathway, and the TCR pathway were associated with immune
system function. Consistent with our findings, previous studies have linked immune system
dysfunctions, such as alterations in cytokine productione, with OCD [25,26]. Moreover, SSRIs
have been shown to exert immunological effects, such as reduced lymphocyte proliferation,
alterations in cytokine secretion, and induction of apoptosis [27]. The axon guidance exhibited
the strongest association with the response to SSRI treatment in OCD patients. In previous
studies, microRNA target genes have been enriched in several pathways during SSRI treatment,
including axon guidance [28]. The calcium signaling pathway was also exhibited significant
association with the response to SSRI treatment in OCD patients. Ca2+ signaling is an impor-
tant intracellular signal that modulates many different cellular functions, including the central
nervous system [29]. SSRIs affect Ca2+ signaling through the regulation of intracellular Ca2+
concentrations, and thereby modulate cell proliferation, immune system function, and gene
transcription, as well as exocytosis at synapses in several cell types, including neurons, astro-
cytes, microglia, platelets, and lymphocytes [30,31,32].
To date, one GWAS has examined treatment responses to SRIs in OCD patients [9]. How-
ever, none of the 42 SNPs identified by Qin and colleagues that exhibited significant associa-
tions (P< 10−4) with SRI responses in OCD patients were among the 178 SNPs that exhibited
nominal associations with SSRI response (P< 10−3) in the present study. These inconsistent
results between studies might be due to differences in sample size (93 vs. 804), antidepressant
drug treatment (SSRI vs. SRI, including serotonin and norepinephrine reuptake inhibitor, and
a tricyclic antidepressant), dosages used for treatment, treatment duration (13.1 ± 8.1 months
vs. lack of detailed information), and/or to differences in the methods used for evaluation and
definition of treatment responses (Y-BOCS scores vs. self-report).
To the best of our knowledge, this is the first GWAS to examine genetic variants contribut-
ing to the response of OCD patients to SSRI combined with antipsychotic therapy. Here, we
identified one suggestive SNP that showed a significant association with patient responses to
such treatment; however, the link between this SNP and patient outcomes did not reach the
genome-wide level of significance. We subsequently detected five pathways that were signifi-
cantly enriched in this treatment group. Of these, the calcium signaling pathway exhibited the
strongest association with patient responses to SSRI combined with antipsychotic therapy.
Notably, this pathway was also associated with the response to SSRI treatment in OCD
patients. Consistent with these findings, previous studies have suggested that antipsychotics
target microglial intracellular Ca2+ signaling [33], and that the combined SSRI-antipsychotic
treatment exerts selective effects on components of the calcium cascade in prefrontal cortex of
rat and human peripheral mononuclear cells [34,35].
There are several limitations to the present study. First, the sample size was limited to enable
the detection of small effects of genetic variants on treatment responses, and we failed to detect
specific genetic variants associated with clinical responses at genome-wide levels of significance
(P< 5 × 10−8) although we revealed several enriched pathways (FDR< 0.05). Further studies
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using a large cohort will therefore be necessary to confirm our findings. Second, the patients
that comprised our cohort were treated in a naturalistic clinical course, and were treated with a
variety of medications. As such, studies using patients who are taking a single antidepressant
are needed. Finally, clinical characteristics of the patients in each pharmacological response
group might affect our results although logistic regression analysis was performed to examine
the effect of SNP on the clinical response with adjustments for sex, age, onset age, and Y-BOCS
baseline score.
In conclusion, we have identified several pathways that may contribute to the response of
OCD patients to SSRI and/or SSRI combined with antipsychotic treatments. Of these, several
were associated with cellular mechanisms known to be affected by SSRIs or antipsychotics. Our
results provide novel insight into the molecular mechanisms underlying clinical response vari-
ability to SSRI and SSRI with antipsychotics in OCD patients.
Supporting Information
S1 Table. Association results of GWAS for the SSRI treatment response in OCD (P
values< 1.0 x 10−3).
(XLSX)
Acknowledgments
The authors would like to thank all the volunteers who understood our study purpose and par-
ticipated in this study, and the physicians who helped us to collect clinical data and blood sam-
ples at the mental hospitals. The authors would also like to thank Mrs. Akemi Okada for her
technical assistance.
Author Contributions
Conceived and designed the experiments: SN TO. Performed the experiments: HU AT AN.
Analyzed the data: HU AT II. Contributed reagents/materials/analysis tools: HUMN SS.
Wrote the paper: HU SN.
References
1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the
National Comorbidity Survey Replication. Mol Psychiatry. 2010; 15: 53–63. doi: 10.1038/mp.2008.94
PMID: 18725912
2. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors
(SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane database Syst Rev.
2008; CD001765. doi: 10.1002/14651858.CD001765.pub3 PMID: 18253995
3. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic
review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psy-
chiatry. 2006; 11: 622–32. doi: 10.1038/sj.mp.4001823 PMID: 16585942
4. Arumugham SS, Reddy JYC. Augmentation strategies in obsessive-compulsive disorder. Expert Rev
Neurother. Informa HealthcareLondon; 2013; 13: 187–202; quiz 203. doi: 10.1586/ern.12.160
5. Fineberg NA, Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, et al. Obsessive-
compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults.
Psychiatry Res. 2015; 227: 114–25. doi: 10.1016/j.psychres.2014.12.003 PMID: 25681005
6. Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmenta-
tion in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analy-
sis. BMC Psychiatry. 2014; 14: 317. doi: 10.1186/s12888-014-0317-5 PMID: 25432131
7. Zai G, Brandl EJ, Müller DJ, Richter MA, Kennedy JL. Pharmacogenetics of antidepressant treatment
in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics. 2014;
15: 1147–57. doi: 10.2217/pgs.14.83 PMID: 25084207
GWAS of Clinical Response in OCD
PLOSONE | DOI:10.1371/journal.pone.0157232 June 9, 2016 7 / 9
8. Zeng P, Zhao Y, Qian C, Zhang L, Zhang R, Gou J, et al. Statistical analysis for genome-wide associa-
tion study. J Biomed Res. 2015; 29: 285–297. doi: 10.7555/JBR.29.20140007 PMID: 26243515
9. Qin H, Samuels JF, Wang Y, Zhu Y, Grados MA, Riddle MA, et al. Whole-genome association analysis
of treatment response in obsessive-compulsive disorder. Mol Psychiatry. Macmillan Publishers Limited;
2015; doi: 10.1038/mp.2015.32
10. Umehara H, Numata S, Tajima A, Kinoshita M, Nakaaki S, Imoto I, et al. No association between the
COMT Val158Met polymorphism and the long-term clinical response in obsessive-compulsive disorder
in the Japanese population. Hum Psychopharmacol. 2015; 30: 372–376. doi: 10.1002/hup.2485 PMID:
26010653
11. Zhang K, Chang S, Guo L, Wang J. I-GSEA4GWAS v2: a web server for functional analysis of SNPs in
trait-associated pathways identified from genome-wide association study. Protein Cell. 2015; 6: 221–4.
doi: 10.1007/s13238-014-0114-4 PMID: 25407412
12. Zhang K, Cui S, Chang S, Zhang L, Wang J. i-GSEA4GWAS: a web server for identification of path-
ways/gene sets associated with traits by applying an improved gene set enrichment analysis to
genome-wide association study. Nucleic Acids Res. 2010; 38: W90–5. doi: 10.1093/nar/gkq324 PMID:
20435672
13. Edwards AC, Aliev F, Wolen AR, Salvatore JE, Gardner CO, McMahon G, et al. Genomic influences on
alcohol problems in a population-based sample of young adults. Addiction. 2015; 110: 461–470. doi:
10.1111/add.12822 PMID: 25439982
14. Kim H-N, Kim B-H, Cho J, Ryu S, Shin H, Sung J, et al. Pathway analysis of genome-wide association
datasets of personality traits. Genes, Brain Behav. Blackwell Publishing Ltd; 2015; 14: 345–356. doi:
10.1111/gbb.12212
15. Kinnersley B, Labussière M, Holroyd A, Di Stefano A-L, Broderick P, Vijayakrishnan J, et al. Genome-
wide association study identifies multiple susceptibility loci for glioma. Nat Commun. 2015; 6: 8559. doi:
10.1038/ncomms9559 PMID: 26424050
16. McPherson R, Tybjaerg-Hansen A. Genetics of Coronary Artery Disease. Circ Res. 2016; 118: 564–
578. doi: 10.1161/CIRCRESAHA.115.306566 PMID: 26892958
17. Shimada-Sugimoto M, Otowa T, Miyagawa T, Khor S-S, Kashiwase K, Sugaya N, et al. Immune-related
pathways including HLA-DRB1*13:02 are associated with panic disorder. Brain Behav Immun. 2015;
46: 96–103. doi: 10.1016/j.bbi.2015.01.002 PMID: 25582808
18. Sim JCH,White SM, Lockhart PJ. ARID1B-mediated disorders: Mutations and possible mechanisms.
Intractable rare Dis Res. 2015; 4: 17–23. doi: 10.5582/irdr.2014.01021 PMID: 25674384
19. Ben-David E, Shifman S. Combined analysis of exome sequencing points toward a major role for tran-
scription regulation during brain development in autism. Mol Psychiatry. Macmillan Publishers Limited;
2013; 18: 1054–6. doi: 10.1038/mp.2012.148
20. Hamdan FF, Srour M, Capo-Chichi J-M, Daoud H, Nassif C, Patry L, et al. De Novo Mutations in Moder-
ate or Severe Intellectual Disability. Cooper GM, editor. PLoS Genet. 2014; 10: e1004772. doi: 10.
1371/journal.pgen.1004772 PMID: 25356899
21. Malli T, Duba H-C, Erdel M, Marschon R, Kranewitter W, Deutschbauer S, et al. Disruption of the
ARID1B and ADAMTS6 loci due to a t(5;6)(q12.3;q25.3) in a patient with developmental delay. Am J
Med Genet A. 2014; 164A: 3126–31. doi: 10.1002/ajmg.a.36738 PMID: 25250687
22. Yuan S, Miller DW, Barnett GH, Hahn JF, Williams BR. Identification and characterization of human
beta 2-chimaerin: association with malignant transformation in astrocytoma. Cancer Res. 1995; 55:
3456–61. Available: http://www.ncbi.nlm.nih.gov/pubmed/7614486 PMID: 7614486
23. Hashimoto R, Yoshida M, Kunugi H, Ozaki N, Yamanouchi Y, Iwata N, et al. A missense polymorphism
(H204R) of a Rho GTPase-activating protein, the chimerin 2 gene, is associated with schizophrenia in
men. Schizophr Res. 2005; 73: 383–5. doi: 10.1016/j.schres.2004.01.017 PMID: 15653288
24. Kanazawa T, Ikeda M, Glatt SJ, Tsutsumi A, Kikuyama H, Kawamura Y, et al. Genome-wide associa-
tion study of atypical psychosis. Am J Med Genet B Neuropsychiatr Genet. 2013; 162B: 679–86. doi:
10.1002/ajmg.b.32164 PMID: 24132900
25. Gray SM, Bloch MH. Systematic review of proinflammatory cytokines in obsessive-compulsive disor-
der. Curr Psychiatry Rep. 2012; 14: 220–8. doi: 10.1007/s11920-012-0272-0 PMID: 22477442
26. Rao NP, Venkatasubramanian G, Ravi V, Kalmady S, Cherian A, YC JR. Plasma cytokine abnormali-
ties in drug-naïve, comorbidity-free obsessive–compulsive disorder. Psychiatry Res. 2015; 229: 949–
952. doi: 10.1016/j.psychres.2015.07.009 PMID: 26187339
27. Gobin V, Van Steendam K, Denys D, Deforce D. Selective serotonin reuptake inhibitors as a novel
class of immunosuppressants. Int Immunopharmacol. 2014; 20: 148–56. doi: 10.1016/j.intimp.2014.02.
030 PMID: 24613205
GWAS of Clinical Response in OCD
PLOSONE | DOI:10.1371/journal.pone.0157232 June 9, 2016 8 / 9
28. Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D, et al. Blood micro-
RNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol.
2013; 23: 602–11. doi: 10.1016/j.euroneuro.2012.06.013 PMID: 22925464
29. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling.
Nat Rev Mol Cell Biol. Nature Publishing Group; 2003; 4: 517–29. doi: 10.1038/nrm1155
30. Schipke CG, Heuser I, Peters O. Antidepressants act on glial cells: SSRIs and serotonin elicit astrocyte
calcium signaling in the mouse prefrontal cortex. J Psychiatr Res. 2011; 45: 242–8. doi: 10.1016/j.
jpsychires.2010.06.005 PMID: 20619420
31. Du T, Liang C, Li B, Hertz L, Peng L. Chronic fluoxetine administration increases expression of the L-
channel gene Cav1.2 in astrocytes from the brain of treated mice and in culture and augments K
(+)-induced increase in [Ca(2+)]i. Cell Calcium. 2014; 55: 166–74. doi: 10.1016/j.ceca.2014.01.002
PMID: 24513410
32. Gobin V, De Bock M, Broeckx BJG, Kiselinova M, De Spiegelaere W, Vandekerckhove L, et al. Fluoxe-
tine suppresses calcium signaling in human T lymphocytes through depletion of intracellular calcium
stores. Cell Calcium. 2015; 58: 254–63. doi: 10.1016/j.ceca.2015.06.003 PMID: 26115837
33. Mizoguchi Y, Kato TA, Horikawa H, Monji A. Microglial intracellular Ca(2+) signaling as a target of anti-
psychotic actions for the treatment of schizophrenia. Front Cell Neurosci. Frontiers; 2014; 8: 370. doi:
10.3389/fncel.2014.00370
34. Chertkow Y, Weinreb O, YoudimMBH, Silver H. Gene expression changes in peripheral mononuclear
cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog
Neuropsychopharmacol Biol Psychiatry. 2007; 31: 1356–62. doi: 10.1016/j.pnpbp.2007.04.016 PMID:
17662512
35. De Bartolomeis A, Avvisati L, Iasevoli F, Tomasetti C. Intracellular pathways of antipsychotic combined
therapies: Implication for psychiatric disorders treatment. European Journal of Pharmacology.
2013. pp. 502–523. doi: 10.1016/j.ejphar.2013.06.034 PMID: 23834777
GWAS of Clinical Response in OCD
PLOSONE | DOI:10.1371/journal.pone.0157232 June 9, 2016 9 / 9
